South Korean (KOSPI) Biotech Industry Analysis

Industry Valuation and Performance

Has the South Korean Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 08 Jul 2026	₩130.4t	₩15.6t	₩238.5b	25.5x	546.9x	8.3x
Fri, 05 Jun 2026	₩140.6t	₩15.7t	₩304.7b	28.6x	461.6x	9x
Sun, 03 May 2026	₩157.4t	₩15.2t	-₩608,655,991,679.00	40.8x	-258.6x	10.4x
Tue, 31 Mar 2026	₩164.1t	₩16.6t	-₩714,955,074,028.92	28.5x	-229.5x	9.9x
Thu, 26 Feb 2026	₩180.6t	₩13.1t	₩203.8b	23.9x	886.3x	13.7x
Sat, 24 Jan 2026	₩166.5t	₩13.1t	₩205.3b	22.8x	810.8x	12.7x
Mon, 22 Dec 2025	₩163.6t	₩13.1t	₩224.5b	24.3x	728.7x	12.5x
Wed, 19 Nov 2025	₩140.6t	₩12.5t	-₩7,943,978,925.00	21.1x	-17693x	11.3x
Fri, 17 Oct 2025	₩118.9t	₩12.4t	-₩30,278,124,823.00	26.9x	-3926.2x	9.6x
Sun, 14 Sep 2025	₩123.6t	₩12.4t	-₩90,788,167,718.00	29.1x	-1361.4x	9.9x
Tue, 12 Aug 2025	₩112.1t	₩11.8t	-₩227,694,607,523.00	23.6x	-492.5x	9.5x
Thu, 10 Jul 2025	₩111.3t	₩11.8t	-₩203,233,047,773.00	24.7x	-547.8x	9.4x
Sat, 07 Jun 2025	₩101.4t	₩11.8t	-₩99,336,020,661.00	24.9x	-1020.6x	8.6x
Mon, 05 May 2025	₩97.2t	₩11.4t	-₩456,504,996,975.00	28.8x	-212.9x	8.5x
Wed, 02 Apr 2025	₩98.2t	₩11.4t	-₩457,605,899,986.00	26.9x	-214.5x	8.6x
Fri, 28 Feb 2025	₩101.3t	₩10.6t	-₩927,517,473,361.00	23.9x	-109.2x	9.5x
Sun, 26 Jan 2025	₩93.8t	₩10.5t	-₩1,004,347,149,181.00	23.1x	-93.4x	9x
Tue, 24 Dec 2024	₩91.2t	₩10.5t	-₩1,005,204,065,171.00	23.6x	-90.8x	8.7x
Thu, 21 Nov 2024	₩88.7t	₩10.4t	-₩913,550,006,707.00	22.9x	-97.1x	8.5x
Sat, 19 Oct 2024	₩98.0t	₩10.3t	-₩653,791,712,887.00	28.4x	-150x	9.5x
Mon, 16 Sep 2024	₩92.4t	₩10.3t	-₩663,381,294,267.00	24.7x	-139.3x	9x
Wed, 14 Aug 2024	₩91.3t	₩9.9t	-₩651,620,427,048.00	23.7x	-140.2x	9.3x
Fri, 12 Jul 2024	₩86.4t	₩9.9t	-₩651,620,427,048.00	22.4x	-132.7x	8.8x
Sun, 09 Jun 2024	₩86.4t	₩9.9t	-₩636,049,297,908.00	22.2x	-135.9x	8.8x
Tue, 07 May 2024	₩82.4t	₩9.6t	-₩567,818,034,968.00	22.4x	-145.1x	8.6x
Thu, 04 Apr 2024	₩80.1t	₩9.6t	-₩665,568,465,312.00	19.7x	-120.3x	8.4x
Sat, 02 Mar 2024	₩78.2t	₩9.7t	-₩534,696,541,747.00	58.3x	-146.2x	8x
Mon, 29 Jan 2024	₩73.9t	₩9.7t	-₩537,261,689,777.00	63.5x	-137.6x	7.6x
Wed, 27 Dec 2023	₩63.9t	₩10.1t	-₩324,942,076,247.00	28.9x	-196.8x	6.3x
Fri, 24 Nov 2023	₩59.6t	₩10.2t	-₩307,988,772,739.00	27.1x	-193.6x	5.9x
Sun, 22 Oct 2023	₩51.1t	₩10.2t	-₩239,053,318,689.00	28.9x	-213.6x	5x
Tue, 19 Sep 2023	₩58.8t	₩10.2t	-₩339,708,651,659.00	31.4x	-173.2x	5.8x
Thu, 17 Aug 2023	₩58.1t	₩10.3t	-₩165,737,957,969.00	29.7x	-350.8x	5.7x
Sat, 15 Jul 2023	₩57.7t	₩10.3t	-₩151,534,704,579.00	27.3x	-381x	5.6x

Current Industry PE

Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 547x which is higher than its 3-year average PE of -439x.

The industry is trading close to its 3-year average PS ratio of 8.8x.

Past Earnings Growth

Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 15% per year.
This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Healthcare industry?


KR Market	-9.68%
Healthcare	-1.18%
Biotech	-2.69%
Biotech	-2.69%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
A068270 Celltrion	₩176.80k	1.3% +₩527.5b	5.4%	PE32x
A302440 SK bioscienceLtd	₩37.95k	3.4% +₩98.1b	-20.3%	PS4.5x
A180400 Dx & Vx	₩2.44k	11.2% +₩24.1b	21.4%	PS8.4x
A217730 Kangstem Biotech	₩2.53k	6.3% +₩14.1b	56.2%	PS69.5x
A291650 Aptamer Sciences	₩1.05k	23.4% +₩12.1b	-13.7%	n/a

Histoindex and D&D Pharmatech Announce Positive Results from Histoindex's AI-Based Quantitative Analysis of Liver Biopsy Samples from the Phase 2 Clinical Trial of Zabopegdutide

HistoIndex and D&D Pharmatech announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 clinical trial of zabopegdutide (DD01) - an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH). Zabopegdutide is a unique, liver-targeted GLP-1/glucagon receptor agonist with a dominant 11:1 GLP-1-to-glucagon potency ratio, which provides both metabolic and hepatic benefits while maintaining a favorable safety and tolerability profile. D&D Pharmatech partnered with HistoIndex to include AI-driven histopathological analysis that now corroborates and extends the Phase 2 zabopegdutide trial findings. As announced last month, a blinded pathologist review of the study's per-protocol population revealed statistically significant improvements in key histologic endpoints including fibrosis improvement and MASH resolution after 48 weeks of treatment. These effects were accompanied by weight loss and improved glycemic control, highlighting its potential as a differentiated therapy for MASH. These results build on earlier findings showing robust liver fat reduction, reduced liver stiffness, and favorable changes in fibrosis markers evident as early as 12 weeks in this trial, underscoring the potential of zabopegdutide as an effective treatment for patients with metabolic liver diseases. In a fully independent assessment, HistoIndex utilized its proprietary AI-powered quantitative tool, qFibrosis, to evaluate fibrosis changes in 48-week liver biopsies. This AI analysis focused on 27 protocol-compliant patients whose baseline fibrosis was confirmed as stage F1 or higher via qFibrosis (16 in the placebo group and 11 in the zabopegdutide dosing group). Reinforcing the positive results of the standard histopathological analysis, HistoIndex's data demonstrated meaningful treatment-related improvements in response rates based on steatosis-corrected qFibrosis stage-level changes, with a significantly greater proportion of patients in the zabopegdutide treatment group achieving =1-stage improvement in fibrosis compared with the placebo group (81.8% vs. 18.8%; p = 0.001). Consistent with these stage-level improvements, a fully quantitative assessment showed significant reductions in qFibrosis® values on a continuous scale among treated patients compared with the placebo group. Specifically, the relative change in steatosis-corrected qFibrosis continuous score from baseline was -41.0% in the zabopegdutide treatment group compared to +9.5% in the placebo group (p < 0.001).

South Korean (KOSPI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development

Now 22% undervalued after recent price drop

JS Link, Inc. announced that it expects to receive KRW 53.392992 billion in funding from Lynas Rare Earths Limited

Investor sentiment deteriorates as stock falls 16%

PharmaResearch Co., Ltd. (KOSDAQ:A214450) signed an agreement to acquire Cosmetic Group USA, Inc.

New minor risk - Share price stability

New minor risk - Share price stability

Histoindex and D&D Pharmatech Announce Positive Results from Histoindex's AI-Based Quantitative Analysis of Liver Biopsy Samples from the Phase 2 Clinical Trial of Zabopegdutide

Price target decreased by 18% to ₩32,750

We Ran A Stock Scan For Earnings Growth And Celltrion (KRX:068270) Passed With Ease

Optipharm.CO.,LTD to Report Q1, 2026 Results on May 26, 2026

New major risk - Revenue and earnings growth

Aptamer Sciences Inc announced that it has received KRW 30.00043989 billion in funding from Alticast Corporation, Daihyun Eng & Const Co., Ltd., K&P Investment Co., Ltd., Vision 2 Co., Ltd., JDK Partners Co., Ltd. and other investors.

New minor risk - Share price stability

Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026

New minor risk - Financial position